Mechanisms and treatment progress of Rituximab-resistance in diffuse large B-cell lymphoma

: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treatment DLBCL, the current first-line treatment used is R-CHOP regimen. This regimen greatly improves the patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exact mechanisms and solutions are still unclear. This review mainly describes the possible mechanisms of rituximab resistance and current new effective treatments for Rituximab-resistance in DLBCL.